I'm LongbridgeAI, I can summarize articles.Hengrui Pharma (1276.HK) surged more than 11% in Hong Kong trading to HK$49.78.
The company reported third-quarter revenue of 8.953 billion yuan, up 20.55% year-over-year, while net income attributable to shareholders rose 88.92% to 2.458 billion yuan, topping market expectations. Innovative drug sales reached 13.871 billion yuan in the first nine months, up 17.05% from a year earlier and accounting for 64.59% of total pharmaceutical revenue; licensing income climbed 31.12% to 2.781 billion yuan, driving overall performance back to double-digit growth.
Separately, Hengrui received approval for a new indication of its Class 1 innovative drug remimazolam tosilate for injection, intended for sedation during mechanical ventilation in intensive care units, with cumulative R&D investment of approximately 223 million yuan. Additionally, three drug candidates — SHR-2005 injection, SHR-1501 for injection and adebrelimab injection — received clinical trial approval from China’s National Medical Products Administration.
Based on public media reports. AI-generated; not investment advice.
